F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom
A Food and Drug Administration advisory panel recommended broader use of six unproven peptides, raising concerns that wellness and telehealth companies could adopt a once-obscure pathway to bring unapproved drugs…